Table 5 Adverse events and dose modifications according to treatment group.
| Â | Group A1 n = 72 | Group A2 n = 71 | Group B n = 67 |
|---|---|---|---|
Total Discontinuation n(%) | 0 | 5 (7.0) | 7 (10)* |
   -anemia | 0 | 3 | 3 |
   -neutropenia | 0 | 1 | 2 |
   -depression | 0 | 0 | 1 |
   -ulcerative colitis | 0 | 1 | 0 |
   -cough | 0 | 0 | 1 |
Dose modification n(%) | Â | Â | Â |
   -Peginterferon | 1 (1) | 2 (3) | 2 (3) |
   -Ribavirin | 2 (3) | 9 (12) | 9 (13) |
Adverse events n(%) | Â | Â | Â |
   -Anemia | 5 (7) | 6 (8) | 6 (9) |
   -Neutropenia | 2 (3) | 1 (1) | 2 (3) |
   -Depression | 2 (3) | 2 (3) | 1 (1) |
   -Cutaneous rash | 0 | 0 | 1 (1) |
   -Alopecia | 0 | 1 (1) | 1 (1) |
   -Fatigue | 2 (3) | 4 (5) | 6 (9) |